| Recruiting | SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors NCT07161713 | Barbara Nemesure | N/A |
| Recruiting | A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodg NCT07283796 | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lym NCT06385522 | Boston Immune Technologies and Therapeutics | Phase 1 |
| Not Yet Recruiting | CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma NCT06486337 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS NCT06731699 | Chengdu FenDi Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Can NCT06119685 | Indapta Therapeutics, INC. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) NCT05879744 | Cullinan Therapeutics Inc. | Phase 1 |
| Active Not Recruiting | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic NCT05665062 | Synthekine | Phase 1 |
| Completed | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies NCT05371054 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL NCT05641428 | University Medical Center Groningen | Phase 2 |
| Withdrawn | A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL NCT05365100 | BioNova Pharmaceuticals (Shanghai) LTD. | Phase 1 / Phase 2 |
| Withdrawn | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL NCT05176691 | Hutchmed | Phase 1 |
| Terminated | First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML NCT04840784 | Shengke Pharmaceuticals Pty Ltd | Phase 1 |
| Withdrawn | A Study of IGN002 for Refractory NHL NCT02847949 | Spectrum Pharmaceuticals, Inc | Phase 1 |
| Unknown | Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. NCT04639739 | Xinqiao Hospital of Chongqing | EARLY_Phase 1 |
| Completed | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL NCT04555811 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Recruiting | Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patien NCT04440436 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients NCT04139252 | Stichting Hemato-Oncologie voor Volwassenen Nederland | — |
| Active Not Recruiting | Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma NCT03789240 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma NCT04002947 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Tr NCT03739502 | University of Rochester | Phase 2 |
| Active Not Recruiting | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL NCT03463057 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Terminated | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractor NCT03465540 | Amgen | Phase 1 |
| Completed | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) NCT03527147 | Acerta Pharma BV | Phase 1 |
| Unknown | Safety and Efficacy Evaluation of Decitabine With R-GDP NCT03535753 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 |
| Terminated | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) NCT02702492 | Karyopharm Therapeutics Inc | Phase 1 |
| Completed | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing NCT02315612 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lym NCT02110563 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Phase 1 |
| Withdrawn | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL NCT01101581 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Umbilical Cord Blood Transplant for Hematological Malignancies NCT00891592 | University of Pennsylvania | Phase 1 |
| Completed | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL NCT00546793 | Gilead Sciences | Phase 1 / Phase 2 |
| Unknown | Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease NCT00515892 | Cambridge Antibody Technology | Phase 1 |
| Terminated | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Gr NCT00814983 | Duke University | Phase 1 / Phase 2 |
| Terminated | Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 NCT00471367 | AstraZeneca | Phase 1 |
| Completed | CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation NCT00333190 | Dana-Farber Cancer Institute | N/A |
| Completed | Safety Study of NHL With 90Y-hLL2 IgG NCT00421395 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Influence of Corn Farming on the Immune System NCT00342121 | National Cancer Institute (NCI) | — |
| Completed | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematolo NCT00513175 | University of California, San Francisco | — |
| Completed | Allogeneic Transplantation From Related Haploidentical Donors NCT00185692 | Stanford University | Phase 2 |